newsfilter
← Latest News
Business Wire·

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the fourth quarter of 2025 $989.0 million in cash, cash equivalents, and short-term investments at end of third quarter